Prof. Michael Ott Joins YolTech as Scientific Advisor

Shanghai, China – Jun 27, 2025 – YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome-editing therapies, today announced the appointment of Prof. Michael Ott to its Scientific Advisory Board. As an internationally recognized leader in liver gene and cell therapy, Prof. Ott will help accelerate the clinical translation of YolTech's gene-editing programs.

Prof. Ott brings more than thirty years of experience in hepatology, gene, and cell therapy, moving early-stage innovations toward clinical application. He currently serves as Professor of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, where he leads the Center for Gene and Cell Therapy of Liver Diseases. His additional leadership roles include principal investigator at TWINCORE – Center for Experimental and Clinical Infection Research, and senior investigator at the REBIRTH Center for Translational Regenerative Medicine.

Prof. Ott’s pioneering work in liver gene therapy, base editing, and organoid engineering has yielded more than 200 peer-reviewed publications. His research has appeared in leading journals including Cell, Cell Stem Cell, Nature Communications, Gastroenterology, Gut, Journal of Hepatology, and Hepatology, with over 9,000 citations to date and an H-index of 48.

Prof. Ott’s appointment reflects YolTech’s commitment to advancing the clinical development of in vivo gene-editing therapies. His expertise will play a key role in guiding YolTech’s research through regulatory milestones and into meaningful patient outcomes.